Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
Critical priority
The issue
New safety information - Product safety
Affected product
CIBINQO (abrocitinib), INREBIC (fedratinib), JAKAVI (ruxolitinib), OLUMIANT (baricitinib), RINVOQ (upadacitinib), XELJANZ/XELJANZ XR (tofacitinib)
Where it was sold
ON, QCReported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.